Giiant Pharma, a preclinical-stage biotech company founded in 2014 and based in Montreal, Quebec, focuses on developing new drug therapeutics with limited systemic exposure to improve the care of patients with inflammatory bowel disease (IBD). With its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drugs that target various biological factors in gastroenterology. Their lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug that offers improved drug tolerability and enhanced therapeutic effects.